References
- Ferlay J, Colombet M, Soerjomataram I, et al. Cancer incidence and mortality patterns in Europe: Estimates for 40 countries and 25 major cancers in 2018] Europ J Cancer. 2018; 103:356–387
- Siegel RL, Miller KD, Jemal A. Cancer Statistics, 2017. CA Cancer J Clin. 2017; 67(1):7–30
- Garavello W, Bertuccio P, Levi F, et al. The oral cancer epidemic in central and eastern Europe. Int J Cancer. 2010; 127(1):160–171
- Taher AN. Head and Neck Cancer: Closer Look at Patients Quality of Life. J Cancer Ther. 2016; 7:121–128
- Elting LS, Chang YC. Costs of Oral Complications of Cancer Therapies: Estimates and a Blueprint for Future Study. JNCI Monographs, 2019; 2019(53): lgz010
- PDQ® Supportive and Palliative Care Editorial Board. PDQ Oral Complications of Chemotherapy and Head/Neck Radiation. Bethesda, MD: National Cancer Institute. Updated <12/16/2016>.
- Vigarios E, Epstein JB, Sibaud V. Oral mucosal changes induced by anticancer targeted therapies and immune checkpoint inhibitors. Support Care Cancer. 2017; 25:1713–1739
- Watters AL, Epstein JB, Agulnik M. Oral complications of targeted cancer therapies: a narrative literature review. Oral Oncol. 2011; 47(6):441–8
- Lacouture ME, Anadkat MJ, Bensadoun RJ, et al. Clinical practice guidelines for the prevention and treatment of EGFR inhibitor-associated dermatologic toxicities. Support Care Cancer. 2011; 19:1079–95 doi:10.1007/s00520-011-1197-6
- Rapoport BL, van Eeden R, Sibaud V, et al. Supportive care for patients undergoing immunotherapy. Support Care Cancer. 2017; 25(10):3017–3030
- Boutros C, Tarhini A, Routier E, et al. Safety profiles of anti-CTLA-4 and anti-PD-1 antibodies alone and in combination. Nat Rev Clin Oncol. 2016; 13(8):473–86 doi:10.1038/nrclinonc.2016.58
- Nicolatou-Galitis O, Kouri M, Papadopoulou E, et al. Osteonecrosis of the jaw related to nonantiresorptive medications: a systematic review. Support Care Cancer. 2019; 27(2):383–394
- Davies M, Duffield EA. Safety of checkpoint inhibitors for cancer treatment: strategies for patient monitoring and management of immune-mediated adverse events. Immunotargets Ther. 2017; 6:51–71 doi:10.2147/ITT.S141577
- Lalla, RV, Bowen J, Barasch A, et al. MASCC/ISOO clinical practice guidelines for the management of mucositis secondary to cancer therapy. Cancer. 2014; 120:1453–61 doi:10.1002/cncr.28592
- Zeller JL. High suicide risk found for patients with head and neck cancer. JAMA. 2006; 296:1716–1717
- Epstein JB, Thariat J, Bensadoun RJ, et al. Oral complications of cancer and cancer therapy: from cancer treatment to survivorship. CA Cancer J Clin. 2012; 62(6):400–22 doi:10.3322/caac.21157
- Saraswat N, Sood A, Kumar D, et al. Clinical Profile of Cutaneous Adverse Effects of Epidermal Growth Factor Receptor Inhibitors: A Prospective Observational Study of 76 Cases. Indian Dermatol Online J. 2019; 10(3):251–255 doi:10.4103/idoj.IDOJ_325_18
- Nicolatou-Galitis O, Kouloulias V, Sotiropoulou-Lountou A, et al. Oral Mucositis, Pain and Xerostomia in 135 Head and Neck Cancer Patients Receiving Radiotherapy with or without Chemotherapy. The Open Cancer Journal. 2011; 4:7–17
- Brailo V, Boras VV, Juras DV, et al. Oral Side Effects of Head and Neck Irradiation. 2017;
http://dx.doi.org/10.5772/intechopen.68961 - Bowen J, Al-Dasooqi N, Bossi P, et al. The pathogenesis of mucositis: updated perspectives and emerging targets. Support Care Cancer. 2019; 27:4023–4033
- Lalla RV, Brennan MT, Gordon SM, et al. Oral Mucositis Due to High-Dose Chemotherapy and/or Head and Neck Radiation Therapy. JNCI Monographs. 2019; 2019(53):lgz011
- Lalla RV, Saunders DP, Peterson DE. Chemotherapy or radiation-induced oral mucositis. Dent. Clin. North Am. 2014; 58:341–9
- Sroussi HY, Epstein J, Bensadoun RJ, et al. Common oral implications of head and neck cancer radiation therapy: mucositis, infections, saliva change, fibrosis, sensory dysfunctions, dental caries, periodontal disease and osteoradionecrosis. Cancer Med. 2017; 6(12):2918–31 doi:10.1002/cam4
- Bressan V, Stevanin S, Bianchi M, et al. The effects of swallowing disorders, dysgeusia, oral mucositis and xerostomia on nutritional status, oral intake and weight loss in head and neck cancer patients: A systematic review. Cancer Treat Rev. 2016; 45:105–19 doi:10.1016/j.ctrv.2016.03.006]
- Vissink A, Jansma J, Spijkervet FKL, et al. Oral sequelae of head and neck radiotherapy. Crit Rev Oral Biol Med 2003; 14(3):199–212
- Lalla RV, Treister N, Sollecito T, et al. Oral complications at six months after radiation therapy for head and neck cancer. Oral Dis. 2017; 23(8):1134–43 doi:10.1111/odi.12710
- Elad S, Zadik Y. Chronic oral mucositis after radiotherapy to the head and neck: a new insight. Support Care Cancer. 2016; 24:4825–30 doi:10.1007/s00520-016-3337-5
- Ang KK, Zhang Q, Rosenthal DI, et al. Randomized phase III trial of concurrent accelerated radiation plus cisplatin with or without cetuximab for stage III to IV head and neck carcinoma: RTOG 0522] J. Clin. Oncol. 2014; 32:2940–50
- Price TJ, Peeters M, Kim TW, et al. Panitumumab versus cetuximab in patients with chemotherapy-refractory wild-type KRAS exon 2 metastatic colorectal cancer (ASPECCT): A randomised, multicentre, open-label, non-inferiority phase 3 study. Lancet Oncol. 2014; 15: 569–579
- Bonner JA, Harari PM, Giralt J, et al. Radiotherapy plus Cetuximab for locoregionally advanced head and neck cancer: 5-year survival data from a phase 3 randomized trial, and relation between cetuximab-induced rash and survival. Lancet Oncol. 2010; 11:21–28
- Magrini SM, Buglione M, Corvò R, et al. Cetuximab and radiotherapy versus cisplatin and radiotherapy for locally advanced head and neck cancer: a randomized phase II trial. J Clin Oncol. 2016; 34:427–435
- Pryor DI, Burmeister E, Burmeister BH, et al. Distinct patterns of stomatitis with concurrent cetuximab and radiotherapy for head and neck squamous cell carcinoma. Oral Oncol. 2011; 47:984–987
- De Sanctis V, Bossi P, Sanguineti G, et al. Mucositis in head and neck cancer patients treated with radiotherapy and systemic therapies: Literature review and consensus statements. Crit Rev Oncol Hematol. 2016; 100:147–66] doi:10.1016/j.critrevonc.2016.01.010
- Zhao B, Zhao H, Zhao J. Serious adverse events and fatal adverse events associated with nivolumab treatment in cancer patients : Nivolumab-related serious/fatal adverse events. J Immunother Cancer. 2018; 6(1):101 doi:10.1186/s40425-018-0421-z
- Motzer RJ, Escudier B, McDermott DF, et al. Nivolumab versus everolimus in advanced renal-cell carcinoma. N Engl J Med. 2015; 373:1803–1813
- Lederhandler MH, Ho A, Brinster N, et al. Severe Oral Mucositis: A Rare Adverse Event of Pembrolizumab. J Drugs Dermatol. 2018; 17(7):807–809
- Bonomi M, Batt K. Supportive Management of Mucositis and Metabolic Derangements in Head and Neck Cancer Patients. Cancers 2015; 7:1743–1757
- Cramer JD, Johnson JT, Nilsen ML. Pain in Head and Neck Cancer Survivors: Prevalence, Predictors, and Quality-of-Life Impact. Otolaryngol Head Neck Surg. 2018; 159(5):853–8 doi:10.1177/0194599818783964
- Jackson LK, Johnson DB, Sosman JA, et al. Oral health in oncology: impact of immunotherapy. Support Care Cancer. 2015; 23(1):1–3 doi:10.1007/s00520-014-2434-6
- Epstein JB, Wilkie DJ, Fischer DJ, et al. Neuropathic and nociceptive pain in head and neck cancer patients receiving radiation therapy. Head Neck Oncol. 2009; 1:26 doi:10.1186/1758-3284-1-26
- Lalla RV, Latortue MC, Hong CH, et al. A systematic review of oral fungal infections in patients receiving cancer therapy. Support Care Cancer. 2010; 18:985–992
- Nicolatou-Galitis O, Athanassiadou P, Kouloulias V, et al. Herpes simplex virus-1 (HSV-1) infection in radiation-induced oral mucositis. Support Care Cancer 2006; 14:753–762.
- Yarom N, Sroussi H, Elad S. Orofacial Pain in Patients with Cancer and Mucosal Diseases. Contemporary Oral Medicine. 2018; DOI: 10.1007/978-3-319-28100-1_39-1
- Viet CT, Corby PM, Akinwande A, et al. Review of Preclinical studies on treatment of Mucositis and Associated Pain. J Dent Res. 2014; 93:868–75.
- Kouri M, Skapinakis P, Damigos D. Effects of the drugs and interventions, used for the management of cancer treatment-related oral mucositis, on the induced oral pain. The internet journal of Pain, Symptom Control and Palliative Care 2012; 9 (1) doi:10.5580/2c2b
- Vadalouca A, Raptis E, Moka E, et al. Pharmacological Treatment of Neuropathic Cancer Pain: A Comprehensive Review of the Current Literature. Pain Pract. 2012; 12:219–251
- Carrozzo M, Eriksen JG, Bensadoun RJ, et al. Oral Mucosal Injury Caused by Targeted Cancer Therapies. J Natl Cancer Inst Monogr. 2019; 2019(53). pii: lgz012 doi:10.1093/jncimonographs/lgz012
- Villa A, Sonis S. Toxicities associated with head and neck cancer treatment and oncology-related clinical trials. Curr Probl Cancer. 2016; 40:244–257
- Villa A, Wolff A, Narayana N, et al. World Workshop on Oral Medicine VI: a systematic review of medication-induced salivary gland dysfunction Oral Diseases. 2016; 22, 365–382
- Pinna R, Campus G, Cumbo E, et al. Xerostomia induced by radiotherapy: an overview of the physiopathology, clinical evidence, and management of the oral damage. Therapeutics and Clinical Risk Management 2015; 11:171–188
- Konings AWT, Coppes RP, Vissink A. On the mechanism of salivary gland radiosensitivity. Int. J. Radiation Oncology Biol Phys 2005; 62(4):1187–1194
- Adel N. Overview of chemotherapy-induced nausea and vomiting and evidence-based therapies. Am J Manag Care. 2017; 23(14 Suppl):259–265
- Moreno J, Sahade M, del Giglio A. Low-dose granisetron for prophylaxis of acute chemotherapy-induced nausea and vomiting: a pilot study. Support Care Cancer. 2005; 13:850–853.
- Jain T, Bhandari A, Ram V, et al. Drug interactions and adverse drug reactions in hospitalized psychiatric patients: a critical element in providing safe medication use. German J Psychiatry. 2011; 14:26–34]
- Ware MA, Fitzcharles MA, Joseph L, Shir Y. The effects of nabilone on sleep in fibromyalgia: results of a randomized controlled trial. Anesthesia & Analgesia 2010; 110:604–10]
- Yamagishi H, Kawaguchi M. Characterization of centraland peripheral-type benzodiazepine receptors in rat salivary glands. Biochem Pharmacol. 1998; 55: 209–214
- Wang X, Zhang ZY, Wang J, et al. Pharmacokinetics, safety, and tolerability of rolapitant administered intravenously following single ascending and multiple ascending doses in healthy subjects. Clin Pharmacol Drug Dev. 2019;8(2):160–171
- Godoy T, Riva A, Ekström J. Atypical antipsychotics-effects of amisulpride on salivary secretion and on clozapine-induced sialorrhea. Oral Dis. 2012; 18(7):680–91 doi:10.1111/j.1601-0825.2012.01926.x
- Schiff E, Mogilner JG, Sella E, et al. Hypnosis for postradiation xerostomia in head and neck cancer patients: a pilot study. Pain Symptom Manage 2009; 37:1086–1092
- Hovan AJ, Williams M, Stevenson-Moore P, et al. A systematic review of dysgeusia induced by cancer therapies. Support Care Cancer 2010; 18:1081–1087
- Nicolatou-Galitis O, Velegraki A, Sotiropoulou-Lontou A, et al. Effect of fluconazole antifungal prophylaxis on oral mucositis in head and neck cancer patients receiving radiotherapy. Support Care Cancer. 2006; 14:44–51
- Wolff A, Joshi RK, Ekström J et al. A Guide to Medications Inducing Salivary Gland Dysfunction, Xerostomia, and Subjective Sialorrhea: A Systematic Review Sponsored by the World Workshop on Oral Medicine VI. Drugs R D. 2017; 17:1–28
- Turner L, Mupparapu M, Akintoye SO. Review of the complications associated with treatment of oropharyngeal cancer: A guide to the dental practitioner. Quintessence Int 2013; 44(3):267–279
- Elad S, Zadik Y, Hewson I, et al. A Systematic Review of Viral infections Associated with oral involvement in cancer patients; a spotlight on herpesviridea. Support Care Cancer. 2010; 18(8):993–1006
- Elad S, Ranna V, Ariyawardana A, et al. A systematic review of oral herpetic viral infections in cancer patients: commonly used outcome measures and interventions. Support Care Cancer. 2017; 25(2):687–700 doi:10.1007/s00520-016-3477-7
- Panghal M, Kaushal V, Kadayan S, et al. Incidence and risk factors for infection in oral cancer patients undergoing different treatments protocols. BMC Oral Health. 2012; 12:22. doi:10.1186/1472-6831-12-22
- Uhlen MM, Tveit AB, Stenhagen KR, et al. Self-induced vomiting and dental erosion-a clinical study. BMC Oral Health. 2014; 14:92 doi:10.1186/1472-6831-14-92
- Galitis E, Droukas V, Tzakis M, et al. Trismus and reduced quality of life in patients with oral squamous cell carcinoma, who received postoperative radiotherapy alone or combined with chemotherapy. Forum of Clinical Oncology. 2017; 8(1):29–36
- Dijkstra PU, Huisman PM, Roodenburg JLN. Criteria for trismus in head and neck oncology. Int J Oral Maxillofac Surg 2006; 35:337–342
- Dhanda J1, Pasquier D2, Newman L3, et al. Current Concepts in Osteoradionecrosis after Head and Neck Radiotherapy. Clin Oncol (R Coll Radiol). 2016; 28(7):459–66 doi:10.1016/j.clon.2016.03.002
- Spijkervet FKL, Brennan MT, Peterson DE, et al. Research Frontiers in Oral Toxicities of Cancer Therapies: Osteoradionecrosis of the Jaws. J Natl Cancer Inst Monogr. 2019; 2019(53): pii: lgz006 doi:10.1093/jncimonographs/lgz006
- Ruggiero SL, Dodson TB, Fantasia J, et al. American Association of Oral and Maxillofacial Surgeons position paper on medication-related osteonecrosis of the jaw—2014 update. J Oral Maxillofac Surg. 2014; 72(10):1938–1956 doi:10.1016/j.joms.2014.04.031
- Nicolatou-Galitis O, Schiødt M, Mendes RA, et al. Medication-related osteonecrosis of the jaw: definition and best practice for prevention, diagnosis, and treatment Oral Surg Oral Med Oral Pathol Oral Radiol. 2019; 127(2):117–135 doi:10.1016/j.oooo.2018.09.008
- Nicolatou-Galitis O, Razis E, Galiti D, et al. Periodontal disease preceding osteonecrosis of the jaw (ONJ) in cancer patients receiving antiresorptives alone or combined with targeted therapies: report of 5 cases and literature review. Oral Surg Oral Med Oral Pathol Oral Radiol. 2015; 120(6):699–706
- Nicolatou-Galitis O, Papadopoulou E, Vardas E, et al. Alveolar bone histological necrosis observed prior to extractions in patients, who received bone-targeting agents. Oral Dis. 2020; doi:10.1111/odi.13294
- Heifetz-Li JJ, Abdelsamie S, Campbell CB, et al. Systematic review of the use of pentoxifylline and tocopherol for the treatment of medication-related osteonecrosis of the jaw. Oral Surg Oral Med Oral Pathol Oral Radiol. 2019; 128(5):491–7.e2 doi:10.1016/j.oooo.2019.08.004
- Fragulidis G, Pantiora E, Michalaki V, et al. Immune-related intestinal pseudo-obstruction associated with nivolumab treatment in a lung cancer patient. J Oncol Pharm Pract. 2019; 25(2):487–491 doi:10.1177/1078155217738325
- Economopoulou P, Nicolatou-Galitis O, Kotsantis I, et al. Nivolumab-related lichen planus of the lip in a patient with head and neck cancer. Oral Oncology. 2020;
http://doi.org/10.1016/j.oraloncology.2020.104623 - Cogen AL, Parekh V, Gangadhar T et al. Lichen planopilaris associated with pembrolizumab in a patient with metastatic melanoma. JAAD Case Rep. 2018; 4(2):132–134 doi:10.1016/j.jdcr.2017.12.002
- Collins LK, Chapman MS, Carter JB, et al. Cutaneous adverse effects of the immune checkpoint inhibitors. Current Problems in Cancer. Curr Probl Cancer. 2017; 41(2):125–128 doi:10.1016/j.currproblcancer.2016.12.001
- Menzies AM, Johnson DB, Ramanujam S, et al. Anti-PD-1 therapy in patients with advanced melanoma and preexisting autoimmune disorders or major toxicity with ipilimumab. Ann Oncol. 2017; 28(2):368–376
- Wang H, Mustafa A, Liu S, et al. Immune Checkpoint Inhibitor Toxicity in Head and Neck Cancer: From Identification to Management. Front Pharmacol. 2019; 10:1254 doi:10.3389/fphar.2019.01254
- Peterson DE, Boers-Doets CB, Bensadoun RJ, et al. Management of oral and gastrointestinal mucosal injury: ESMO Clinical Practice Guidelines for diagnosis, treatment, and follow-up. Ann Oncol. 2015; 26 Suppl 5:v139–51 doi:10.1093/annonc/mdv202
- Basile D, Di Nardo P, Corvaja C, et al. Mucosal Injury during Anti-Cancer Treatment: From Pathobiology to Bedside. Cancers (Basel). 2019; 11(6): pii:E857 doi:10.3390/cancers11060857
- Larson PJ, Miaskowski C, MacPhail L, et al. The PRO-SELF Mouth Aware program: an effective approach for reducing chemotherapy-induced mucositis. Cancer Nurs. 1998; 21(4):263–268.
- Hong CHL, Gueiros LA, Fulton JS, et al. Systematic review of basic oral care for the management of oral mucositis in cancer patients and clinical practice guidelines. Support Care Cancer. 2019; 27(10):3949–3967 doi:10.1007/s00520-019-04848-4
- Lopez BC, Esteve CG, Perez MGS. Dental treatment considerations in the chemotherapy patient. J Clin Exp Dent. 2010; 3:31–42
- Caribé-Gomes F, Chimenos-Küstner E, López-López J, et al. Dental management of the complications of radio and chemotherapy in oral cancer. Med Oral. 2003; 8(3):178–187